ArticleBMC infectious diseases2026
Association of visceral obesity with Helicobacter pylori seropositivity and mortality in US adults.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIt remains unclear whether Helicobacter pylori (H. pylori) serostatus modifies the obesity-mortality relationship. This study aimed to evaluate the interaction between H. pylori serostatus and visceral obesity indicators in relation to mortality.
methodsData were analyzed on 2,161 adults of the National Health and Nutrition Examination Survey (NHANES) 1999–2000 cycle, and followed up through 2018. Logistic regression adjusted for multiple covariates evaluated the relationship between visceral obesity and H. pylori seropositivity. Cox regression with restricted cubic splines (RCS), stratified by H. pylori serostatus, were used to evaluate survival outcomes.
resultsWaist-triglyceride index (WTI) and visceral adiposity index (VAI) were both significantly related to H. pylori seropositivity, and only WTI showed an interaction with serostatus in relation to mortality. Among seropositive individuals, the highest WTI tertile was associated with a 66% higher risk of all-cause mortality than the lowest (95% CI: 1.149–2.397; P = 0.007). No significant association was observed in seronegative individuals.
conclusionsOur findings demonstrated that H. pylori serum status was the effect modification factor associated with visceral obesity and mortality. This increased risk was evident at high visceral adiposity, as measured by WTI. Therefore, WTI may help identify high-risk individuals among those with H. pylori seropositivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.